Introduction
============

Ankylosing spondylitis (AS), an inflammatory and immune disease that mainly affects axial joints,[@b1-dddt-10-933] is characterized by a strong correlation between chronic inflammation and abnormal new bone formation.[@b2-dddt-10-933] However, it is not entirely understood.

As an important mediator of inflammation, prostaglandin E2 (PGE-2) modulates the anabolic/catabolic process, which occurs in the bone forming and absorption,[@b3-dddt-10-933] and is the most abundant among prostaglandins in osteoblasts.[@b4-dddt-10-933] PGE-2 promotes bone remodeling through inducing osteoblast cell differentiation[@b5-dddt-10-933],[@b6-dddt-10-933] and is widely involved in the heterotopic ossification.[@b7-dddt-10-933],[@b8-dddt-10-933] Moreover, PGE-2 plays a more essential role in the development of heterotopic ossification than other prostaglandins in the rabbit model.[@b9-dddt-10-933] PGE-2 could exert antiapoptotic effects on bone marrow stem cells, leading to an increase in the number of cells and subsequent osteoblastic cell differentiation.[@b10-dddt-10-933] Beside this, PGE-2 is commonly used for osteogenic induction via upregulation of bone morphogenetic protein 2 (BMP-2),[@b11-dddt-10-933] which has the ability to induce osteoblastic precursor cell differentiation and in vitro osteogenesis.[@b12-dddt-10-933],[@b13-dddt-10-933]

To date, the possibility of PGE-2 involvement in the pathophysiogenesis and AS progression has been investigated.[@b14-dddt-10-933] Genome-wide association studies on AS recently reported that gene prostaglandin E receptor 4, one of the four genes that encode the PGE-2 receptors (EP1--EP4),[@b15-dddt-10-933] was associated with AS.[@b16-dddt-10-933] Indeed, EP4-knockout mice exhibited a marked reduction in bone resorption, causing impaired formation of osteoclasts, matrix metalloproteinase MMP-2 and MMP-13.[@b17-dddt-10-933],[@b18-dddt-10-933] Furthermore, PGE-2 downregulated Wnt/β-catenin inhibitors, including dickkopf-1 and sclerostin, which have been proven to be two crucial negative regulated factors in AS bone forming,[@b19-dddt-10-933],[@b20-dddt-10-933] through AKT/PI3K and Wnt signaling cross-interactions.[@b21-dddt-10-933] Nonsteroidal anti-inflammatory drugs (NSAIDs) were frequently used for patients with AS to inhibit heterotopic ossification over the years, which supports the possibility that prostaglandins were local mediators of inflammation and bone remodeling involved in this process.[@b22-dddt-10-933]--[@b24-dddt-10-933]

Although NSAIDs are generally used for AS patients, common side effects associated with the long-term use of NSAIDs include gastrointestinal and cardiovascular toxicities.[@b25-dddt-10-933],[@b26-dddt-10-933] Searching for new drugs with low side effects to target AS inflammation and new bone formation are thus urgent tasks.

As complementary and alternative medications, traditional Chinese medicine not only has a long history of therapeutic use but also is acceptable and tolerated by patients.[@b27-dddt-10-933] In People's Republic of China, *Tripterygium wilfordii*, which is a medicinal herb, has been used in the treatment of inflammatory and rheumatic diseases for thousands of years. *T*. *wilfordii* is reported to improve physical activity and relieve symptoms in patients with rheumatoid arthritis (RA)[@b28-dddt-10-933] and AS.[@b29-dddt-10-933] Celastrol, one of the active compounds present in *T*. *wilfordii*, has been identified to have strong anti-inflammatory activity[@b30-dddt-10-933],[@b31-dddt-10-933] and reduce the severity of clinical arthritis.[@b32-dddt-10-933],[@b33-dddt-10-933] Previous reports demonstrated that celastrol strongly suppressed lipopolysaccharide-induced expression of PGE-2 at low concentrations,[@b34-dddt-10-933] via the downregulation of COX-1 and -2 activation.[@b35-dddt-10-933] This provided a theoretical basis for understanding the inhibitory effects of celastrol against PGE-2-induced osteogenesis.

So far, most studies related to celastrol in inflammatory disease were mainly focused on RA.[@b36-dddt-10-933] However, the effects of celastrol on AS bone forming have not been documented before. Therefore, our study was carried out to investigate the effect of celastrol on the proliferation and osteogenesis of isolated AS fibroblasts induced by PGE-2 for the first time. To elucidate the mechanisms, we examined the inhibitory role of celastrol on isolated AS fibroblast proliferation and in vitro osteogenic differentiation by using different modern techniques.

Materials and methods
=====================

Isolation and culture of hip synovial fibroblasts
-------------------------------------------------

Six AS patients with hip joint involved received total hip replacement in our hospital. In this study, patients were referred to a rheumatologist if they were: 1) age ≤45 years, 2) symptoms duration ≥3 months, and 3) asymmetrical arthritis pain plus more than one spondyloarthritis (SpA) feature ([Table 1](#t1-dddt-10-933){ref-type="table"}). All the surgical procedures and experiments were approved by the Ethics Committee, Southern Medical University, People's Republic of China. All patients signed the informed consent. Briefly, the hip capsule synovium tissues were excised from the hip synovial tissue. Synovium was minced and digested with 3 mg/mL collagenase (type I; Sigma-aldrich, Shanghai, China) in sterile phosphate-buffered saline (PBS) for 2.5 hours at 37°C. The isolated tissues were passed through a 70 mm cell strainer (Becton Dickinson, Franklin Lakes, NJ, USA) to form a single-cell suspension. The released cells were washed with PBS, centrifuged at 300× *g* for 5 minutes, and subsequently resuspended in Dulbecco's Modified Eagle's Medium (Thermo Fisher Scientific, Waltham, MA, USA), a medium containing 10% fetal bovine serum, and supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mM [l]{.smallcaps}-glutamine (all of them from Thermo Fisher Scientific). The isolated cells were incubated at 37°C under 5% CO~2~ to form colonies. The old culture medium was removed and PBS was used to wash the cells one to two times. Then trypsin--EDTA (1 mL/25 cm^2^) was added to wash the bottom of the culture dish. Then trypsin--EDTA was removed and the culture dish was put into the 37°C cell incubator for 2--3 minutes. Trypsin was inhibited by adding a medium containing 10% FBS. Fresh medium was added and cells were transferred into a new culture dish with normal conditions. The cultured medium with PGE-2 was changed every 2 days throughout the experiments. Flow cytometry was used for fibroblast sorting and identification marked by CD90 and CD106 as previously described.[@b37-dddt-10-933],[@b38-dddt-10-933]

Cultured fibroblasts were stimulated with PGE-2 (Sigma) at concentrations of 10^−7^ M as previously described[@b39-dddt-10-933] and then incubated in 3 mL of Dulbecco's Modified Eagle's Medium supplemented with antibiotics and fungizone. PGE-2 was added for proliferation and osteogenesis in the whole cell culture process. The medium was changed every 2 days throughout the experiments.

Preparation of celastrol and indometacin
----------------------------------------

A stock solution of celastrol (20 mg in 0.6 mL of dimethyl sulfoxide \[DMSO\]) was prepared and stored as small aliquots at −20°C until used (Sigma-Aldrich Co., St Louis, MO, USA). Different doses of celastrol (0.5, 1.0, and 2.0 μM) used in vitro in this study were based on that used in a previous study.[@b34-dddt-10-933] Celastrol stock was diluted in PBS, and PBS--DMSO (1.2%) served as its negative control. Indometacin (1.0 μM) was selected as a positive control. DMSO, 1.0 μM of nonselective NSAIDs--indometacin, and the indicated concentrations of celastrol (0.5, 1.0, and 2.0 μM) were added on day 12.

Proliferation assay
-------------------

Cells were seeded in 24-well plates at a density of 1×10^5^ cells/well. Cell proliferation was investigated using an MTS assay on days 12, 14, 17, and 20, respectively. In brief, cells were added to 500 μL of MTS solution and incubated for 4 hours. After that, cells were washed with PBS and added to 500 μL of DMSO to remove the MTS solution. The optical density was measured at 570 nm using a Sunrise absorbance reader (Tecan Group Ltd., Shanghai, People's Republic of China).

Alkaline phosphatase activity
-----------------------------

Alkaline phosphatase (ALP) activity was examined according to a published protocol.[@b13-dddt-10-933] Culture medium was aspirated from AS fibroblasts that were incubated in plates. The plates were rinsed with 150 mM NaCl and 1 mL of reaction buffer containing 0.25 M 2-methyl-2-amino propanol and 1 mM magnesium chloride. An amount of 2.5 mg/mL of p-nitrophenyl phosphate (Sigma) at pH 10.3 was added to each well at 37°C, respectively. The reaction was stopped after 30 minutes by adding 0.5 mL of 0.3 M Na~3~PO~4~ at pH 12.3. ALP activity was assessed by measuring the absorbance of light at 410 nm and comparing the experimental samples with standard solutions of p-nitrophenol and a blank group. ALP was normalized for protein concentration using BCA Protein Assay Reagent (Pierce, Rockford, IL, USA), compared with the standard protein, and measured by spectrophotometry at 562 nm.

RNA isolation and quantitative real-time PCR
--------------------------------------------

Total RNA was isolated from the cells by using Trizol (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized from 4 μg of total RNA using 200 U of reverse transcriptase (Invitrogen) according to the manufacturer's instructions. The gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) as a housekeeping gene. The sequences of forward and reverse primers used were as follows: BMP-2, 5′-CAGCTTCCACCATGAAGAAT-3′ (F), and 5′-CCAACCTGGTGTCCAAAAGT-3′ (R); runt-related transcription factor 2 (Runx-2), 5′-CTCCCTGAACTCTGCACCAA-3′ (F), and 5′-GTTCTGAAGCACCTGAAATGCG-3′ (R); collagen type I alpha 1, 5′-CCTGGATGCCATCAAAGTCT-3′ (F), and 5′-ACTGCAACTGGAATCCATCG-3′ (R); osteocalcin, 5′-ATGAGAGCCCTCACACTCCT-3′ (F), and 5′-CTTGGACACAAAGGCTGCAC-3′ (R); and *GAPDH*, 5′-CCATGGAGAAGGCTGGGG-3′ (F), and 5′-CAAAGTTGTCATGGATGACC-3′ (R).

Alizarin red staining
---------------------

For Alizarin red staining, the cells were fixed for 1 hour using 70% ethanol at 4°C. After washing with distilled water for three times, Alizarin red solution (40 mM) was added for 10 minutes. Cells were rinsed with distilled water and subsequently washed with PBS. The stained cells were observed under an inverted microscope. Photomicrographs were obtained by using a charge-coupled device camera. Thereafter, Alizarin red was eluted with 10% cetylpyridinium chloride, and the optical density value was read at 510 nm for quantified analysis of ossification activity.

Western blot analysis
---------------------

Whole cells were lysed using RIPA buffer (10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 0.5% sodium dodecyl sulfate, 1% NP-40, 1% Na-deoxycholate, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride, 1 μg/mL of pepstatin, and 1 μg/mL of leupeptin). Secretory protein was extracted by precipitation with trichloroacetic acid. Western blot analysis was performed with anti-PGE-2, anti-AKT, anti-PI3K, anti-GSK-3β, anti-β-catenin, anti-DKK-1, anti-SOST, or anti-β-actin antibodies (all from Abcam, Cambridge, UK).

Statistical analysis
--------------------

Data in each group were shown as the mean ± standard deviation calculated from the results of the six samples. Statistical significance was assessed by one-way analysis of variance, and multiple comparison tests were employed by Scheffe's method. A *P*-value of \<0.05 was considered significant.

Results
=======

Effect of celastrol on proliferation of isolated AS fibroblasts
---------------------------------------------------------------

Hip synovial fibroblasts were successfully primary cultured ([Figure 1](#f1-dddt-10-933){ref-type="fig"}). In order to investigate the potential effect of celastrol on proliferation of isolated AS fibroblasts, we conducted various concentrations of celastrol, indometacin 1.0 μM, normal and DMSO control, and cell viability was determined using MTS assay. Treatment with 2.0 μM celastrol most greatly decreased cell viability, in comparison with other controls ([Figures 2](#f2-dddt-10-933){ref-type="fig"} and [3](#f3-dddt-10-933){ref-type="fig"}). To further explore the effect of celastrol on cells, we monitored cell proliferation on day 14 using EdU incorporation assay ([Figure 4](#f4-dddt-10-933){ref-type="fig"}). It was also shown that treatment with 2.0 μM celastrol greatly decreased cell viability, and cells treated with 2.0 μM celastrol led to a significant percentage reduction of EdU-positive AS fibroblasts. An amount of 1.0 μM celastrol exhibited stronger ability to suppress AS fibroblast proliferation compared with 1.0 μM indometacin determined by MTS and EdU analysis ([Figures 2](#f2-dddt-10-933){ref-type="fig"}[](#f3-dddt-10-933){ref-type="fig"}--[4](#f4-dddt-10-933){ref-type="fig"}). The treatment with 1.0 μM indometacin showed slightly more decreased cell viability as well as percentage reduction of EdU-positive AS fibroblasts and was not statistically significant as compared with that in 0.5 μM celastrol ([Figures 2](#f2-dddt-10-933){ref-type="fig"}[](#f3-dddt-10-933){ref-type="fig"}--[4](#f4-dddt-10-933){ref-type="fig"}).

Effect of celastrol on PGE-2-induced osteogenesis in isolated AS fibroblasts
----------------------------------------------------------------------------

We performed several assays to assess the effect of celastrol on the osteogenesis of AS fibroblasts.

### ALP activity

The results demonstrated that large, medium, and small doses of celastrol as well as indometacin had significant inhibitory effects on the ALP activity of PGE-2-induced AS fibroblasts at 2, 3, and 4 weeks ([Figure 5](#f5-dddt-10-933){ref-type="fig"}). The ALP activity was inhibited by celastrol in a dose-dependent manner. As shown in [Figure 5](#f5-dddt-10-933){ref-type="fig"}, its activity decreased gradually when stimulated with increasing doses of celastrol. Similarly, data obtained from the medium dose of celastrol and indometacin had a similar effect on the ALP activity.

### Alizarin red staining

The results demonstrated that large, medium, and small doses of celastrol as well as indometacin had a significant inhibitory effect on the alizarin red staining activity of PGE-2-induced AS fibroblasts on days 14, 21, and 28. Mineralization had the largest decline in 2.0 μM celastrol. The medium dose of celastrol and indometacin had a similar effect on the ARS activity. Celastrol 2.0 μM exhibited stronger inhibition effects of mineralization than indometacin 1.0 μM ([Figure 6](#f6-dddt-10-933){ref-type="fig"}).

### Real-time PCR

The mRNA expressions of BMP-2, type I collagen, Runx-2, and osteocalcin were involved in PGE-2-induced AS fibroblasts. Therefore, to investigate whether celastrol could inhibit PGE-2-induced AS fibroblasts, mRNA levels of BMP-2, type I collagen, Runx-2, and osteocalcin were assessed by real-time PCR on days 14, 21, and 28. Treatment with 1.0 μM celastrol suppressed mRNA and protein expression in a time-dependent manner ([Figure 7](#f7-dddt-10-933){ref-type="fig"}). The results indicated that the group with 1.0 μM celastrol had a significantly higher mRNA expression of BMP-2, type I collagen, Runx-2, and osteocalcin than the normal group. Especially, celastrol treatment significantly reduced the expression of BMP-2 on days 21 and 28 (^\*\*^*P*\<0.01). These findings indicated that the medium dose of celastrol had a significant inhibitory effect on mRNA expressions of BMP-2, type I collagen, Runx-2, and osteocalcin in PGE-2-induced AS fibroblasts compared with the normal group (^\*^*P*\<0.05).

Effect of celastrol on PGE-2, Wnt, and AKT/PI3K signaling cross-interactions by Western blot analysis
-----------------------------------------------------------------------------------------------------

In order to explore the potential mechanism of celastrol on osteogenesis in isolated AS fibroblasts, we performed Western blot analysis to examine the expression of related proteins pretreated with a medium dose of celastrol. The untreated bands were used as controls. The intensity of the bands was quantified by densitometric analysis and normalized against the appropriate controls. The average results from six independent experiments are shown in [Figure 8](#f8-dddt-10-933){ref-type="fig"} and [Table S1](#SD1-dddt-10-933){ref-type="supplementary-material"}. Accordingly, we found the expression of PGE-2, AKT, and PI3K reduced substantially. The expression of GSK-3β increased significantly, whereas the level of β-catenin decreased with time. On the other hand, the expression of DKK-1 and sclerostin, Wnt signaling inhibitors, elevated gradually.

Discussion
==========

In terms of AS, inflammation is frequently on the sacroiliac joints,[@b40-dddt-10-933] anterior and posterior vertebral corners of the spine,[@b41-dddt-10-933] and hip joints[@b42-dddt-10-933] where syndesmophytes develop. Previous studies have proposed a positive association between vertebral corner inflammation of baseline magnetic resonance imaging and subsequent development of new syndesmophytes,[@b43-dddt-10-933]--[@b45-dddt-10-933] which supports a hypothesis that inflammation is implicated in new bone formation of patients with AS. In recent years, the inflammation biomarkers related to AS bone turnover have been mostly focused on tumor necrosis factor-α. Nevertheless, interventions targeting tumor necrosis factor-α were not expected to obtain favorable prognosis on AS radiographic progression.[@b46-dddt-10-933],[@b47-dddt-10-933] To date, NSAIDs acted as the most effective drugs to prevent structural damage in AS patients[@b22-dddt-10-933]--[@b24-dddt-10-933] by inhibiting COX-1 and -2 to reduce the production of PGE-2. This fact indicated that PGE-2 may play a crucial role in the interplay between inflammation and new bone formation in AS.

This study was aimed to investigate the underlying mechanism by which celastrol exerts its activity on AS fibroblast proliferation and osteogenesis, thus finding new potential ways for the treatment of AS.

Celastrol is one of the remedial ingredients isolated from the root of the Thunder God Vine, also named "Lei Gong Teng" in Chinese. The Thunder God Vine is a perennial vine of Celastraceae family (bittersweet), which has been widely used in People's Republic of China for the treatment of autoimmune and inflammatory diseases for centuries.[@b48-dddt-10-933] The plant is poisonous, but its root pulp contains several therapeutically active compounds. Moreover, celastrol is the most widely studied and promising compound isolated from the Thunder God Vine.[@b28-dddt-10-933] Celastrol contains electrophilic sites within the rings of quinone methide structure and it can react with the nucleophilic thiol groups of cysteine residues and form covalent Michael adducts.[@b49-dddt-10-933] Its inhibitory effects against COX-1, COX-2, and PGE-2 have been identified,[@b33-dddt-10-933],[@b34-dddt-10-933] which are similar with NSAIDs. The difference is that celastrol is also endowed with cytotoxic-like function and could exhibit anticancer effects.[@b49-dddt-10-933]--[@b51-dddt-10-933]

In the present study, results showed that celastrol effectively inhibited proliferation and bone formation of PGE-2-induced AS fibroblasts. Notably, to elucidate the potential mechanism of antibone forming action of celastrol, we found that cross-interactions of Wnt, BMP-2, and AKT/PI3K signaling pathways were involved in this process.

We selected AS fibroblasts as target cells. In addition to mesenchymal stem cells, fibroblast are another category with osteogenic potentials, especially in pathological conditions.[@b52-dddt-10-933] Fibroblasts are the most common cells in connective tissues around joints. Fibroblasts and osteoblasts all originate from mesenchymal stem cells with overlapping phenotypes and similar differentiation pathways, which enables possible mutual biological transformation.[@b53-dddt-10-933] Fibroblasts could also provide surroundings for calcium deposition and bone formation by producing extracellular matrix vesicles and type I collagen, which plays a crucial role in trauma repair and ectopic ossification in certain pathophysiologic processes.[@b54-dddt-10-933],[@b55-dddt-10-933] In addition, fibroblasts also express osteogenic markers Runx-2 and osteocalcin (OCN). It has been reported that NIH3T3 cells (a fibroblast cell line derived from mouse) could express osteogenic markers and develop mineralization deposits in vitro induced by dexamethasone and 1,25(OH)2D3.[@b56-dddt-10-933] Human derived ligament fibroblasts could also develop osteogenic differentiation in conditioned medium.[@b57-dddt-10-933] Previous studies also identified that activities of fibroblast proliferation and collagen synthesis could be enhanced by inflammatory mediators in vitro, which develop bone formation, proliferation of the connective tissues, or fibrosis.[@b58-dddt-10-933],[@b59-dddt-10-933] An early immunohistochemistry analysis by Ono et al[@b60-dddt-10-933] found four cell types are present in the ossified ligament tissues: chondrocytes, chondrocyte-like cells, fibroblast-like cells, and fibroblasts. According to the distribution of cells, the authors believed that chondrocytes are derived from fibroblasts. In addition, chondrocyte-like cells and fibroblast-like cells are the same cell types, both originating from fibroblasts.[@b56-dddt-10-933] Other experimental and animal studies have also proved that fibroblasts have osteogenic potential in certain conditions.[@b61-dddt-10-933],[@b62-dddt-10-933] All these findings suggest fibroblasts in AS may convert to osteoblast-like type cells and express osteogenic makers under certain conditions.

Fibroblasts isolated from AS patients were significantly affected by PGE-2-induced expression of osteogenic phenotype. The results of our study highlighted a marked reduction in cell proliferation and distinctive attenuation of osteogenic activity of celastrol-treated AS fibroblasts compared to negative controls in a time- and dose-dependent manner. In addition, a medium dose of celastrol exhibited similar effects in both ARS staining and ALP activity, as indometacin. As mentioned above, we hypothesized that this protection against abnormal new bone formation may be mediated via the cross-interactions of PGE-2 and different signaling pathways, such as Wnt, BMP-2, and AKT/PI3K. The Wnt pathway and PGE-2 have mutual cross-interactions. Especially, canonical Wnt proteins promoted PI3K/Akt activity, resulting in GSK-3β phosphorylation and the growth of free β-catenin levels.[@b63-dddt-10-933] On the other hand, PGE-2 activated the trimetric G-protein by binding to its EP2 receptor. The Gβγ subunits activated PI3-kinase which in turn activated Akt. After that, Akt phosphorylated GSK-3β leading to inhibiting its phosphorylation of β-catenin.[@b64-dddt-10-933] All in all, the PI3K-Akt signaling pathway is involved in PGE-2-induced osteogenic differentiation. Besides, PGE-2 exerted its anabolic effects to induce BMP-2 and COX-2 via activating osteoblastic EP2 and EP4 receptors.[@b65-dddt-10-933] BMP-2 in turn induced COX-2 expression, resulting in accelerating the production of PGE-2.[@b66-dddt-10-933]

Previous studies widely reported the effect of celastrol on osteoclasts in RA models. Nanjundaiah et al[@b67-dddt-10-933] found celastrol could inhibit inflammation-induced osteoclasto-genesis in arthritic rats via stimulating RANKL production and increasing RANKL/OPG ratio. Moreover, Gan et al[@b68-dddt-10-933] observed that celastrol not only directly suppressed the formation and function of osteoclasts, but also reduced the RANKL-induced expression of osteoclastic genes and transcriptional factors. In our study, celastrol inhibited fibroblast proliferation and osteogenesis, which implicated that celastrol performed "complete inhibition" of osteoblasts, fibroblasts, and osteoclasts. This was why celastrol impaired their further activities and functions.

AS damages bone in the same way as RA in the initial stage of the disease. Nevertheless, some cases are followed by abnormal bone formation, which is probably linked with the subtle modulation via inflammation and bone metabolism on the different stages of disease. Although the underlying mechanism has not been clearly delineated, we hypothesize that it is associated with the attenuation of PGE-2. Our results supported this proposition. A low dose of exogenous PGE-2 (\<0.5 mg) stimulated bone apposition. Instead, high doses caused bone resorption, which is expected to be identified in a further study.

In our study, several limitations should be taken into account. First, we only took in vitro AS fibroblasts as study samples. Therefore, animal models or other in vivo models should be performed to substantiate these results. Second, we only demonstrated the role of celastrol on PGE-2 and downstream proteins of PGE-2. Despite all this, other inflammation markers related to bone metabolism are worthy of further in-depth study. Last, we only obtained tissues from AS patients due to ethical reasons. Additional tissue samples from healthy controls, RA, OA patients, and so on would be helpful to identify whether the findings are specific to AS.

In conclusion, our study provided a novel insight regarding the inhibitory effect of celastrol on the proliferation of AS fibroblasts and PEG-2-induced osteogenesis. We demonstrated for the first time that celastrol inhibited PGE-2-induced osteogenic differentiation in AS fibroblasts. Meanwhile, celastrol could also reduce the number of fibroblasts in a time- and dose-dependent manner. These results revealed that celastrol inhibits further differentiation of fibroblasts into osteogenic phenotype. In future studies, application of celastrol might be a promising approach in the treatment of new bone formation in AS by performing pharmacokinetic and toxicological analyses in animals and humans as well as randomized control studies.

Supplementary material
======================

###### 

Raw Data Of Western Blot Analysis Results with 1.0 μM celastrol compared with untreated group

  Integral optical density     Sample      1             2             3             4               5             6             Mean ± standard deviation   Student's *t*-test   Mean          Standard deviation
  ---------------------------- ----------- ------------- ------------- ------------- --------------- ------------- ------------- --------------------------- -------------------- ------------- --------------------
  PGE-2                        Untreated   77,962.000    121,535.000   154,375.000   172,965.000     209,880.000   259,912.000                                                    166,104.833   64,274.925
                               2w          80,463.000    108,513.393   137,790.179   152,916.071     183,369.643   230,414.286                                                    148,911.095   53,454.639
                               3w          50,277.000    102,007.143   97,456.429    142,857.000     138,725.000   184,820.000                                                    119,357.095   46,401.450
                               4w          19,529.339    46,443.388    58,524.380    68,235.124      79,473.967    99,511.983                                                     61,953.030    27,601.439
  AKT                          Untreated   75,130.000    121,535.000   154,467.000   173,849.000     271,412.000   300,198.000                                                    182,765.167   87,021.237
                               2w          73,375.000    89,588.000    95,846.000    138,928.000     161,910.000   208,731.000                                                    128,063.000   51,536.457
                               3w          35,984.000    67,491.765    98,782.000    88,292.000      113,370.588   176,478.000                                                    96,733.059    47,448.950
                               4w          16,084.074    40,302.222    51,192.593    60,956.667      70,521.852    88,330.000                                                     54,564.568    25,024.513
  PI3K                         Untreated   100,313.000   125,077.000   156,274.000   175,708.000     211,910.000   281,901.000                                                    175,197.167   65,133.028
                               2w          55,197.391    103,168.696   131,959.130   147,187.826     176,207.826   221,958.261                                                    139,279.855   57,774.388
                               3w          59,597.924    89,402.076    103,023.529   115,707.958     134,275.433   169,376.471                                                    111,897.232   37,786.666
                               4w          23,267.000    55,707.500    69,714.500    82,346.500      96,014.500    120,000.000                                                    74,508.333    33,453.162
  GSK-3β                       Untreated   73,265.000    125,363.000   156,274.000   180,334.000     212,244.000   306,148.000                                                    175,604.667   79,721.611
                               2w          95,143.179    146,213.078   141,615.558   198,020.000     241,396.843   326,957.159                                                    191,557.636   83,312.457
                               3w          108,984.286   168,448.571   192,251.429   226,865.714     276,860.000   403,350.000                                                    229,460.000   102,090.639
                               4w          148,190.987   210,502.146   283,343.348   303,182.403     343,927.039   550,534.335                                                    306,613.376   138,403.780
  β-catenin                    Untreated   81,591.000    127,190.000   158,698.000   183,174.000     212,998.000   281,072.000                                                    174,120.500   69,331.209
                               2w          82,537.963    111,828.704   140,525.000   157,359.259     187,846.296   286,344.444                                                    161,073.611   71,328.128
                               3w          74,752.381    102,926.984   119,524.603   153,410.317     158,575.397   218,142.063                                                    137,888.624   50,309.480
                               4w          15,518.519    38,137.037    50,235.185    60,865.926      69,654.074    86,392.222                                                     534,67.160    24,845.021
  DKK-1                        Untreated   83,856.000    127,417.000   159,792.000   185,990.000     213,286.000   299,094.000                                                    178,239.167   74,465.589
                               2w          158,499.200   211,062.400   260,292.800   299,499.200     354,587.200   508,168.000                                                    298,684.800   123,136.173
                               3w          17,6312.281   234,470.175   285,489.474   328,710.526     406,571.930   574,935.088                                                    334,414.912   141,752.052
                               4w          217,241.379   270,662.562   322,753.695   366,940.887     454,352.217   626,766.010                                                    376,452.791   147,131.875
  SOST                         Untreated   913,43.000    129,557.000   159,792.000   186,066.000     213,286.000   351,542.000                                                    188,597.667   90,488.470
                               2w          153,626.362   178,861.656   200,989.924   254,365.468     282,563.998   420,596.405                                                    248,500.635   96,870.683
                               3w          204,862.000   270,450.000   325,814.000   375,354.000     463,492.000   683,864.000                                                    387,306.000   170,068.344
                               4w          231,531.429   313,048.571   368,368.571   413,237.143     514,397.143   721,402.857                                                    426,997.619   172,702.782
  β-actin                      Untreated   86,493.000    124,619.000   148,869.000   171,025.000     202,315.000   296,635.000                                                    171,659.333   72,862.317
                               2w          86,493.000    123,294.000   148,208.000   169,948.000     202,173.000   296,319.000                                                    171,072.500   72,958.144
                               3w          85,229.000    121,535.000   147,596.000   169,017.000     199,805.000   294189.000                                                     169,561.833   72,591.980
                               4w          85,659.000    122,272.000   148,145.000   169,266.000     200,881.000   294,312.000                                                    170,089.167   72,493.597
  PGE-2/β-actin                Untreated   0.901         0.975         1.037         1.011           1.037         0.876         0.97±0.07                                        0.973         0.070
                               2w          0.930         0.880         0.930         0.900           0.907         0.778         0.89±0.06                   **0.015**            0.887         0.057
                               3w          0.590         0.839         0.660         0.845           0.694         0.628         0.71±0.11                   **0.015**            0.710         0.108
                               4w          0.228         0.380         0.395         0.403           0.396         0.338         0.36±0.07                   **0.000**            0.357         0.067
  AKT/β-actin                  Untreated   0.869         0.975         1.038         1.017           1.342         1.012         1.04±0.16                                        1.042         0.159
                               2w          0.848         0.727         0.647         0.817           0.801         0.704         0.76±0.08                   **0.011**            0.757         0.077
                               3w          0.422         0.555         0.669         0.522           0.567         0.600         0.56±0.08                   **0.025**            0.556         0.082
                               4w          0.188         0.330         0.346         0.360           0.351         0.300         0.31±0.06                   **0.000**            0.312         0.065
  PI3K/β-actin                 Untreated   1.160         1.004         1.050         1.027           1.047         0.950         1.04±0.07                                        1.040         0.069
                               2w          0.638         0.837         0.890         0.866           0.872         0.749         0.81±0.1                    **0.011**            0.809         0.097
                               3w          0.699         0.736         0.698         0.685           0.672         0.576         0.68±0.05                   **0.024**            0.678         0.054
                               4w          0.272         0.456         0.471         0.486           0.478         0.408         0.43±0.08                   **0.001**            0.428         0.082
  GSK-3β/β-actin               Untreated   0.847         1.006         1.050         1.054           1.049         1.032         1.01±0.08                                        1.006         0.080
                               2w          1.100         1.186         0.956         1.165           1.194         1.103         1.12±0.09                   **0.070**            1.117         0.089
                               3w          1.279         1.386         1.303         1.342           1.386         1.371         1.34±0.05                   **0.000**            1.344         0.045
                               4w          1.730         1.722         1.913         1.791           1.712         1.871         1.79±0.08                   **0.000**            1.790         0.085
  β-catenin/β-actin            Untreated   0.943         1.021         1.066         1.071           1.053         0.948         1.02±0.06                                        1.017         0.058
                               2w          0.954         0.907         0.948         0.926           0.929         0.966         0.94±0.02                   **0.047**            0.938         0.022
                               3w          0.877         0.847         0.810         0.908           0.794         0.742         0.83±0.06                   **0.015**            0.829         0.060
                               4w          0.181         0.312         0.339         0.360           0.347         0.294         0.31±0.07                   **0.000**            0.305         0.065
  DKK1/β-actin                 Untreated   0.970         1.022         1.073         1.088           1.054         1.008         1.04±0.04                                        1.036         0.044
                               2w          1.833         1.712         1.756         1.762           1.754         1.715         1.76±0.04                   **0.000**            1.755         0.044
                               3w          2.069         1.929         1.934         1.945           2.035         1.954         1.98±0.06                   **0.000**            1.978         0.059
                               4w          2.536         2.214         2.179         2.168           2.262         2.130         2.25±0.15                   **0.001**            2.248         0.148
  SOST/β-actin                 Untreated   1.056         1.040         1.073         1.088           1.054         1.185         1.08±0.05                                        1.083         0.053
                               2w          1.776         1.451         1.356         1.497           1.398         1.419         1.48±0.15                   **0.002**            1.483         0.151
                               3w          2.404         2.225         2.207         2.221           2.320         2.325         2.28±0.08                   **0.000**            2.284         0.078
                               4w          2.703         2.560         2.487         2.441           2.561         2.451         2.53±0.1                    **0.000**            2.534         0.098
  Relative PGE-2/β-actin       Untreated   1.000         1.000         1.000         1.000           1.000         1.000         1±0                                              1.000         0.000
                               2w          1.032         0.902         0.897         0.890           0.874         0.887         0.91±0.06                   **0.016**            0.914         0.059
                               3w          0.654         0.861         0.637         0.836           0.669         0.717         0.73±0.1                    **0.016**            0.729         0.096
                               4w          0.253         0.389         0.381         0.399           0.381         0.386         0.36±0.06                   **0.000**            0.365         0.055
  Relative AKT/β-actin         Untreated   1.000         1.000         1.000         1.000           1.000         1.000         1±0                                              1.000         0.000
                               2w          0.977         0.745         0.623         0.804           0.597         0.696         0.74±0.14                   **0.006**            0.740         0.139
                               3w          0.486         0.569         0.645         0.514           0.423         0.593         0.54±0.08                   **0.036**            0.538         0.080
                               4w          0.216         0.338         0.333         0.354           0.262         0.297         0.3±0.05                    **0.000**            0.300         0.053
  Relative PI3K/β-actin        Untreated   1.000         1.000         1.000         1.000           1.000         1.000         1±0                                              1.000         0.000
                               2w          0.550         0.834         0.848         0.843           0.832         0.788         0.78±0.12                   **0.006**            0.783         0.116
                               3w          0.603         0.733         0.665         0.666           0.642         0.606         0.65±0.05                   **0.021**            0.652         0.048
                               4w          0.234         0.454         0.448         0.474           0.456         0.429         0.42±0.09                   **0.001**            0.416         0.090
  Relative GSK-3β/β-actin      Untreated   1.000         1.000         1.000         1.000           1.000         1.000         1±0                                              1.000         0.000
                               2w          1.299         1.179         0.910         1.105           1.138         1.069         1.12±0.13                   **0.077**            1.117         0.128
                               3w          1.510         1.378         1.241         1.273           1.321         1.328         1.34±0.09                   **0.000**            1.342         0.095
                               4w          2.042         1.711         1.822         1.699           1.632         1.812         1.79±0.14                   **0.000**            1.786         0.145
  Relative β-catenin/β-actin   Untreated   1.000         1.000         1.000         1.000           1.000         1.000         1±0                                              1.000         0.000
                               2w          1.012         0.889         0.889         0.865           0.883         1.020         0.93±0.07                   **0.049**            0.926         0.070
                               3w          0.930         0.830         0.760         0.847           0.754         0.783         0.82±0.07                   **0.017**            0.817         0.067
                               4w          0.192         0.306         0.318         0.336           0.329         0.310         0.3±0.05                    **0.000**            0.298         0.053
  Relative DKK1/β-actin        Untreated   1.000         1.000         1.000         1.000           1.000         1.000         1±0                                              1.000         0.000
                               2w          1.890         1.674         1.636         1.621           1.664         1.701         1.7±0.1                     **0.000**            1.698         0.098
                               3w          2.134         1.887         1.802         1.788           1.930         1.938         1.91±0.13                   **0.000**            1.913         0.125
                               4w          2.616         2.165         2.030         1.993           2.145         2.112         2.18±0.23                   **0.002**            2.177         0.225
  Relative SOST/β-actin        Untreated   1.000         1.000         1.000         1.000           1.000         1.000         1±0                                              1.000         0.000
                               2w          1.682         1.395         1.263         1.376           1.326         1.198         1.37±0.17                   **0.003**            1.373         0.168
                               3w          2.276         2.140         2.057         2.041           2.200         1.962         2.11±0.12                   **0.000**            2.113         0.115
                               4w          2.559         2.463         2.317         2.244           2.429         2.068         2.35±0.18                   **0.001**            2.347         0.176
                               **PGE-2**   **AKT**       **PI3K**      **GSK-3β**    **β-catenin**   **DKK1**      **SOST**                                                                     
  Untreated                    1.000       1.000         1.000         1.000         1.000           1.000         1.000                                                                        
  2w                           0.914       0.740         0.783         1.117         0.926           1.698         1.373                                                                        
  3w                           0.729       0.538         0.652         1.342         0.817           1.913         2.113                                                                        
  4w                           0.365       0.300         0.416         1.786         0.298           2.177         2.347                                                                        
  Untreated                    0.000       0.000         0.000         0.000         0.000           0.000         0.000                                                                        
  2w                           0.059       0.139         0.116         0.128         0.070           0.098         0.168                                                                        
  3w                           0.096       0.080         0.048         0.095         0.067           0.125         0.115                                                                        
  4w                           0.055       0.053         0.090         0.145         0.053           0.225         0.176                                                                        

**Note:** The bolding indicates that *P*\<0.05 was regarded as significant.

**Abbreviations:** PGE-2, prostaglandin E2; w, weeks.
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![Fibroblasts were successfully cultured and subcultured regularly by changing the culture medium.\
**Notes:** (**A**) Fibroblasts were isolated from the hip synovium tissue. (**B**) third generation of cultured fibroblasts. Scale bar is 100 μm and magnification is 10^10^. (**C**) and (**D**) indicates CD90-FITC-positive cells and self control, respectively. The line is the gate that contains wanted CD90-FITC-positive cells. R2 is the classification of CD90-FITC-positive cells. (**E**) and (**F**) indicates CD 106-negative and CD90-positive cells, respectively.](dddt-10-933Fig1){#f1-dddt-10-933}

![Cell proliferation growth curve treated by various doses of Celastrol, 1.0 μM Indometacin as well as negative controls.\
**Note:** This experiment was repeated six times.\
**Abbreviation:** DMSO, dimethyl sulfoxide.](dddt-10-933Fig2){#f2-dddt-10-933}

![Celastrol inhibits cell proliferation by an MTS assay.\
**Notes:** The results of the MTS assay indicated that celastrol inhibits fibroblast proliferation in a time- and dose-dependent manner. This experiment was repeated six times. Values are shown as mean ± standard deviation. The error bars represent the standard deviation of the mean. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 versus normal control group. OD Value (%) = (mean OD value at different time + mean OD value at baseline) ×100% (the same sample).\
**Abbreviations:** DMSO, dimethyl sulfoxide; OD, optical density.](dddt-10-933Fig3){#f3-dddt-10-933}

![Cell proliferation is measured by performing an EdU incorporation assay on day 14.\
**Notes:** Positive DAPI staining was in blue in the nucleus, showing the numbers of cells as the control. Red fluorescence revealed the number of EdU-positive cells (all ×100). Histogram indicates the positive rates of EdU-positive cells (^\*^*P*\<0.05). ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 versus normal control group. The scale bar is 50 μm.\
**Abbreviation:** DMSO, dimethyl sulfoxide.](dddt-10-933Fig4){#f4-dddt-10-933}

![Effect of different doses of celastrol on ALP activity in isolated ankylosing spondylitis fibroblasts compared with indometacin and negative control.\
**Notes:** ALP activity was shown as a specific activity (unit/g protein). The concentration of ALP in each chamber was plotted as the mean ± standard deviation in six replicated experiments. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 versus normal control group. Data from indometacin (1.0 μM) and different doses of celastrol as well as negative controls were compared at the same time duration and evaluated by one-way analysis of variance. Multiple comparisons were performed by Scheffe's method.\
**Abbreviations:** DMSO, dimethyl sulfoxide; ALP, alkaline phosphatase.](dddt-10-933Fig5){#f5-dddt-10-933}

![Effect of different doses of celastrol on Alizarin red staining in isolated ankylosing spondylitis fibroblasts compared with indometacin and negative control.\
**Notes:** Dimethyl sulfoxide (DMSO), 1.0 μM of nonselective nonsteroidal anti-inflammatory drugs--indometacin, and the indicated concentrations of celastrol (0.5, 1.0, and 2.0 μM) were added on day 12. Representative images of Alizarin red staining were demonstrated on days 14, 21, and 28. The area of mineral deposit in each well was calculated by randomly choosing from four microscopic fields. The Alizarin red was eluted with 10% cetylpyridinium chloride, and the OD value was read at 510 nm for quantification. Each bar represents the mean ± standard deviation in six replicated experiments. Data from cultured fibroblasts treated with different drugs were compared at the same time duration and evaluated by one-way analysis of variance. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 versus control group. The scale bar is 100 μm.\
**Abbreviation:** OD, optical density.](dddt-10-933Fig6){#f6-dddt-10-933}

![An amount of 1.0 μM celastrol inhibits mRNA expressions of osteogenic genes in prostaglandin E2-induced ankylosing spondylitis fibroblasts compared with untreated control.\
**Notes:** The mRNA expressions of bone morphogenetic protein 2 (BMP-2), type I collagen, Runx-2, and osteocalcin were detected by real-time PCR on days 14, 21, and 28. The relative expression level was calculated from the threshold cycle (Ct) value of each PCR product and normalized with that of GAPDH by using a comparative Ct method. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01.](dddt-10-933Fig7){#f7-dddt-10-933}

![Celastrol (1.0 μM) impacts the expression of related proteins in isolated fibroblasts.\
**Notes:** Cultured fibroblasts were pretreated with 1.0 μM celastrol. The protein levels were detected by Western blot analysis. The bands of Western blot analysis were digitally detected and normalized with that of β-actin. Each bar represents the mean ± standard deviation in six replicated experiments. Data were evaluated by one-way analysis of variance, and multiple comparisons were performed by Scheffe's method. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 versus normal control group.\
**Abbreviation:** PGE-2, prostaglandin E2.](dddt-10-933Fig8){#f8-dddt-10-933}

###### 

Basic clinical data for AS patients

  Patient number         1           2           3           4           5           6
  ---------------------- ----------- ----------- ----------- ----------- ----------- -----------
  Diagnosis              AS          AS          AS          AS          AS          AS
  Age, in years          43          39          35          41          37          26
  Sex (male or female)   M           F           M           M           M           M
  BMI                    20.2        21.3        20.7        21.9        19.7        18.5
  HLA-B27                \+          \+          \+          \+          \+          \+
  BASDAI                 4.1         3.7         4.5         5.6         5.5         4.9
  NSAIDs used            Yes         Yes         Yes         Yes         Yes         Yes
  DMARDs used            MTX + SSZ   MTX + SSZ   MTX + SSZ   MTX + SSZ   MTX + SSZ   MTX + SSZ
  Corticosteroids used   No          No          No          No          No          No
  TNF-blockade used      No          No          No          No          No          No
  mSASS scores           42          33          39          48          55          22
  New York grading       IV          IV          IV          IV          IV          IV

**Note:** + is HLA-B27 positive and − is HLA-B27 negative.

**Abbreviations:** AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DMARDs, Disease Modifying Antirheumatic Drugs; mSASS, modified Stoke Ankylosing Spondylitis Spinal Score; NY, New York; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; SSZ, sulfasalazine; TNF, tumor necrosis factor.
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